



Newsletter



Ethical approval for France and Denmark!

We are more than happy to announce the ethical approval obtained by Lille and Odense! This means the STEPS-EA trial is allowed to start in every participating center in France and Denmark; making it possible for Lille, Marseille, Paris, Odense and Copenhagen to start in January 2022. More good news is that we included our 5th patient in the trial! At this moment 2 patients have received the steroid injections and 3 patients have been randomized in the control group.

Participating centers

Centers who will be ready to include patients from January 2022:

- Odense University Hospital and Rigshospitalet Copenhagen (Denmark)
- Centre Hospitalier Universitaire de Lille, Assistance Publique - Hôpitaux de Paris and Hôpitaux Universitaires de Marseille (France)
- Helsinki University Hospital (Finland)

The following centers have started the local ethical approval process:

- University Hospital Vall d'Hebron Barcelona (Spain)
- Sant Joan de Déu Barcelona (Spain)
- Clinical Hospital Center Zagreb (Croatia)
- Karolinska Institutet Stockholm (Sweden)
- Bambino Gesù Hospital (Italy)
- Amsterdam UMC (The Netherlands)

The legal department is reviewing the trial agreement in the following centers:

- Medical University of Vienna (Austria)
- Hospital Universitario La Paz Madrid (Spain)
- University Hospital Santaros Klinikos Vilnius (Lithuania).

Lastly, Lund (Sweden), London (United Kingdom), Vienna SMZ Ost (Austria), Padua (Italy), Athens (Greece) and Sydney (Australia) have expressed their interest in participating in the trial.

For any questions or if you are interested in participation, please contact us. We are happy to help you with the logistics in any way possible.

The STEPS-EA trial team steps.ea@erasmusmc.nl

Merry Christmas and a Happy New Year!



The STEPS-EA trial team wishes you a Merry Christmas and a Happy New Year! May 2022 be a fruitful academic year!

Road to success



The STEPS-EA trial: intralesional STERoid injections to Prevent refractory Strictures in patients with Esophageal Atresia

→ 1:1 randomization to injection with 10 mg/ml TAC (Kenacort-A 10) prior to balloon dilatation and balloon dilatation without any injection